Instil Bio and ImmuneOnco report Phase 2 NSCLC trial of IMM2510 on track; initial data expected 2H 2025

Instil Bio, Inc.

Phase 2 trial of IMM2510 + chemo in first-line NSCLC in China to complete enrollment of ~60 patients by Q3 2025.
Initial safety and efficacy results from the Phase 2 trial anticipated in second half of 2025.
ORR of 23.1% observed in Phase 1 monotherapy for relapsed/refractory NSCLC (efficacy evaluable n=13).
US Phase 1b/2 monotherapy dose optimization trial of IMM2510 expected to start before end of 2025, subject to regulatory approvals.
Phase 3 trial of IMM2510 + chemo in first-line NSCLC anticipated to start in mid-2026 in China, pending regulatory discussions.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.